Fat metabolism: nootropics and compounds | sci-wiki

5-Amino/MIC

5-Amino/MIC is a combination formulation that pairs the NNMT inhibitor 5-Amino-1MQ with the classic lipotropic trio MIC, namely methionine, inositol, and choline. It is designed to attack body fat from two directions at once; 5-Amino-1MQ reprograms fat-cell metabolism by raising NAD, while the MIC lipotropics support the liver's handling and export of fat. Popular in physique and weight-management circles, it bundles a modern metabolic target with time-tested fat-metabolism cofactors in a single stack.

1 outlet

Blend

Lipo MIC Prime

Lipo MIC Prime is a lipotropic injectable that combines the classic MIC nutrients (methionine, inositol, and choline) with L-carnitine and vitamin B12 to support fat metabolism and energy during weight management. The MIC compounds help the liver process and export fat, L-carnitine ferries fatty acids into the mitochondria to be burned, and B12 supports energy production and methylation. Bundling several complementary metabolic cofactors into one formulation, it is a convenient, nutrient-based adjunct to a diet-and-exercise program.

1 outlet

Blend

Lipo-Nex

Lipo-Nex is a lipotropic injectable built around a high-carnitine base combined with choline, inositol, yohimbine, ATP, and vitamin B12, formulated to support fat mobilization and energy. L-carnitine shuttles fatty acids into the mitochondria to be burned, while yohimbine blocks the alpha-2 adrenoceptors that normally restrain fat release, an effect most pronounced in stubborn areas and in the fasted state. With its added stimulant character from yohimbine, Lipo-Nex is a targeted option for those seeking assertive metabolic and fat-mobilization support.

1 outlet

Peptide

ACE-031

ACE-031 (ramatercept) is a powerful myostatin-blocking biologic, a soluble decoy of the activin receptor type IIB that traps myostatin and related muscle-limiting proteins before they can signal. By lifting this natural brake on growth, a single dose produced measurable gains in lean muscle mass and thigh muscle volume in human trials. Originally developed as a therapy for muscular dystrophy, it remains one of the most sought-after experimental agents for dramatic, receptor-level muscle building.

3 outlets

Peptide

AOD-9604

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to the C-terminal lipolytic domain (residues 176-191) with an added tyrosine, engineered to trigger fat breakdown without the blood-sugar and growth side effects of full growth hormone. In obese animals it reduced body weight and body fat and increased fat oxidation, while notably not impairing insulin sensitivity the way intact growth hormone does [1][3]. It is marketed as a fat-loss and recovery peptide, though it never gained approval as an anti-obesity drug and its human weight-loss data are limited [4].

6 outlets

Mitochondrial

GW-0742

GW-0742 is a potent PPAR-delta agonist and a close cousin of Cardarine, sitting right at the center of the "exercise in a bottle" conversation in metabolic research. By switching on the genes for fat burning and mitochondrial fuel use, it makes muscle lean on fat and spare glycogen, and in rodents the endurance and fat-loss numbers are genuinely eye-catching. As a proof of concept for activating the body's fat-burning machinery, GW-0742 is a fascinating and closely watched research compound.

2 outlets

Peptide

HGH Fragment 176-191

HGH Fragment 176-191 is the C-terminal lipolytic region of human growth hormone, isolated to keep the fat-burning action while shedding the hormone's growth and blood-sugar effects [1][2]. In obese animal models this fragment, developed clinically as AOD9604, reduces body weight and body fat, boosts fat oxidation, and stimulates lipolysis without raising blood glucose or acting through the growth hormone receptor [1][2][3]. It is this clean separation of fat metabolism from classic GH signaling that has made the fragment a focused research tool for obesity [3][4].

4 outlets

Mitochondrial

SR-9009

SR-9009, also known as Stenabolic, is a synthetic agonist of the nuclear receptors REV-ERB-alpha and REV-ERB-beta, core repressive components of the circadian clock that link the body's timekeeping to metabolism. By activating REV-ERB, it reprograms clock and metabolic gene expression across the hypothalamus, liver, skeletal muscle, and adipose tissue; in mice it increases energy expenditure, reduces fat mass, improves dyslipidemia and hyperglycemia, alters sleep architecture, and raises mitochondrial content and endurance capacity through the Rev-erb-alpha to LKB1-AMPK-SIRT1-PGC-1alpha pathway. Pharmacological REV-ERB activation has also proven selectively lethal to cancer cells and oncogene-induced senescent cells by suppressing autophagy and de novo lipogenesis. Studies using conditional REV-ERB knockouts have shown that some of SR-9009's actions persist without the receptors, indicating REV-ERB-independent off-target effects and reinforcing its status as a research tool rather than an approved therapeutic.

2 outlets

Mitochondrial

SLU-PP-915

SLU-PP-915 is an orally active, chemically distinct pan-agonist of the estrogen-related receptors (ERR-alpha, beta, and gamma) and the successor to SLU-PP-332, engineered as a next-generation exercise mimetic. Activating these master regulators of endurance metabolism, it raises aerobic capacity, mitochondrial gene expression, and fat oxidation in animal studies, and it synergizes with actual exercise training. Its key advance over the earlier compound is oral bioavailability, making it a far more practical tool for chronic study of pharmacological exercise.

1 outlet